ImpediMed (ASX:IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status, has announced it has signed Regional Health Care Group as its exclusive distribution partner for SOZO in Australia and New Zealand.
Under the terms of the agreement, Regional Health Care Group (RHCG) will be responsible for the sale of SOZO systems with L-Dex to customers across Australia and New Zealand.
"The two companies will work closely together to market SOZO in the region, initially focused on lymphoedema sales, with ImpediMed providing marketing and training materials, and assisting in other marketing efforts," said the company in a statement.
“Regional Health Care Group has a long history as a top performing distributor for a number of medical products, and is the right strategic partner to introduce our next generation platform to this and other important markets,” said Richard Carreon, managing director and CEO of ImpediMed.
“This partnership bolsters the resources we have dedicated to establishing SOZO as the standard of care in the ANZ market. We also see this as a strategic partnership for the longer term with Regional Health Care Group playing a key role in working with us to build the business across a number of chronic disease markets.” added Stephen Doorey, general manager at RHCG.
“At Regional Health Care Group, we are always looking to partner with innovative companies to introduce new and unique technologies to the Australian and New Zealand markets. ImpediMed’s SOZO platform is a truly exciting medical technology that is well proven, accurate and will help many patients around the world. We believe that this technology will be a valuable addition to our expanding portfolio of medical devices and technologies, and we look forward to working alongside ImpediMed to educate the medical community and patient population about the benefits of SOZO."